How to buy Regeneron Pharmaceuticals (REGN) shares in Australia
Learn how to easily invest in Regeneron Pharmaceuticals shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Regeneron Pharmaceuticals Inc is a biotechnology business with stocks listed in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$611.22 – a decrease of 3.2% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Regeneron Pharmaceuticals
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Regeneron Pharmaceuticals. Find the share by name or ticker symbol: REGN. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Regeneron Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$598.44, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Regeneron Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Regeneron Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Regeneron Pharmaceuticals key stats
- Compare share trading platforms
- Is Regeneron Pharmaceuticals stock a buy or sell?
- Regeneron Pharmaceuticals performance over time
- Is Regeneron Pharmaceuticals suitable for ethical investing?
- Are Regeneron Pharmaceuticals shares over-valued?
- Regeneron Pharmaceuticals's financials
- How volatile are Regeneron Pharmaceuticals shares?
- Does Regeneron Pharmaceuticals pay a dividend?
- Other common questions
Regeneron Pharmaceuticals stock price (NASDAQ:REGN)Use our graph to track the performance of REGN stocks over time.
Regeneron Pharmaceuticals shares at a glance
|52-week range||US$441 - US$686.62|
|50-day moving average||US$634.2396|
|200-day moving average||US$582.6738|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$62.526|
Where to buy Regeneron Pharmaceuticals stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Regeneron Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Regeneron Pharmaceuticals price performance over time
|1 week (2022-01-12)||-3.20%|
|1 month (2021-12-16)||-3.25%|
|3 months (2021-10-19)||10.71%|
|6 months (2021-07-19)||4.44%|
|1 year (2021-01-19)||14.48%|
|2 years (2020-01-17)||58.37%|
|3 years (2019-01-18)||45.93%|
|5 years (2017-01-19)||68.19%|
Stocks similar to Regeneron Pharmaceuticals
Is Regeneron Pharmaceuticals under- or over-valued?
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's P/E ratio
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, Regeneron Pharmaceuticals shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's PEG ratio
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2061. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$7.5 billion (£5.5 billion).
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Regeneron Pharmaceuticals financials
|Revenue TTM||US$13.4 billion|
|Operating margin TTM||53.85%|
|Gross profit TTM||US$4.5 billion|
|Return on assets TTM||22.61%|
|Return on equity TTM||51.09%|
|Market capitalisation||US$66.2 billion|
TTM: trailing 12 months
Regeneron Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Regeneron Pharmaceuticals's total ESG risk score
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 12/31/2018) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Regeneron Pharmaceuticals's environmental score
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's social score
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Regeneron Pharmaceuticals's governance score
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||22.33|
|Total ESG percentile||26.82|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Regeneron Pharmaceuticals share dividends
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Regeneron Pharmaceuticals share price volatility
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as US$441 up to US$686.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.1723. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals in the news
Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis
Sanofi Says Second Phase 3 Dupixent Trial Confirms Improvements For Patients With Prurigo Nodularis
Newman Dignan & Sheerar, Inc. Buys iShares Core MSCI Emerging Markets ETF, Applied Finance ...
Frequently asked questions
More guides on Finder
Interview: RAQ founder talks Abbie Chatfield swim collection
RAQ Apparel founder Sophia Argyropoulos chats the inspo for Abbie Chatfield swimwear collab and the secret to finding the perfect bikini.
7 ways to elevate your home movie experience [SPONSORED] Turn your low-key movie nights into a main attraction that can keep everyone entertained.
American Express Qantas Corporate Gold Card
With a 100,000 bonus Membership Rewards offer and complimentary Qantas Business Rewards membership, is this the right card for your business?
How to watch Liverpool vs Arsenal Carabao Cup live and free in Australia
Liverpool and Arsenal battle for a place in the League Cup final.
Rapid antigen tests: When will RAT stock be available? [UPDATED]
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
New on Netflix, Prime Video, Disney Plus, Stan, Foxtel, BINGE and more in January 2022
You can easily elevate your binge-watching game in the New Year.
Where to watch DC series Peacemaker online in Australia
He believes in peace at any cost – no matter how many people he has to kill to get it.
How to watch Melbourne Renegades vs Melbourne Stars BBL live and match preview
Both Melbourne teams are fighting for their seasons as we embark on derby number 2
10 beauty trends that’ll pop off in 2022
From clean beauty to bedazzled everything, these are the makeup looks will take over 2022 and the products you need to pull them off.
Compare rapid antigen test brands: How do they stack up?
Not all tests are created equal here are the different brands compared.
Ask an Expert